Value Rotation Drives VFVA Higher as Tech Valuations Pause
14.02.2026 - 22:51:03
Key facts at a glance:
- Close: 142.66 USD (+1.00%)
- 52-Week Range: 96.08 USD – 144.80 USD
- Year-to-Date Performance: +7.44%
- Support Zone: around 137.39 USD
All-time high discussion
With the latest close, VFVA edges closer to its 52-week peak of 144.80 USD. The recent price action points to a steadier near-term uptrend. In an environment where the broader market’s price-to-earnings ratio hovers near 22, investors are increasingly seeking segments with more attractive valuations. VFVA serves as an alternative to the richly priced major indices.
Should investors sell immediately? Or is it worth buying Vanguard U.S. Value Factor?
Active management at a low cost
Unlike traditional passive funds, VFVA employs an active quantitative approach. The fund systematically selects stocks that appear undervalued relative to their fundamentals. A key selling point is its cost efficiency: an expense ratio of 0.13%, making it one of the least expensive active options available. This aligns with Vanguard CEO Salim Ramji’s 2026 strategy to emphasize cost-effective active management in order to win market share from pricier competitors.
Macro backdrop supports value-oriented names
The current market environment favors tangible, asset-backed equities. January inflation data came in at +2.4% year over year, broadly in line with forecasts. While growth-focused indices like the Nasdaq Composite slipped on Friday (-0.22%), value-oriented strategies benefited from a sector rotation. The fund’s active methodology enables dynamic shifts into undervalued industries, counterbalancing the high valuations seen in technology stocks.
What to watch next week
The 144.80 USD level remains a focal point. A sustained breakout beyond this resistance could unlock additional upside. Investors will also monitor whether the decoupling from the S&P 500 persists, which would signal a longer-lasting capital reallocation. Other pivotal variables include shifts in interest-rate expectations and any changes in the fund’s top holdings, which include names such as CVS Health and Verizon.
Ad
Vanguard U.S. Value Factor Stock: Buy or Sell?! New Vanguard U.S. Value Factor Analysis from February 14 delivers the answer:
The latest Vanguard U.S. Value Factor figures speak for themselves: Urgent action needed for Vanguard U.S. Value Factor investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 14.
Vanguard U.S. Value Factor: Buy or sell? Read more here...
